Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.54 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.46 |
| ▸ | RBP4 | P02753 | 2/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19205362 | 0.89 | PTGDR2 (0.46) | PTGDR2PTGDRSCN9AMGLLCHRM2 | |
| SCHEMBL19205325 | 0.87 | PTGDR2 (0.55) | PTGDR2PTGDRRBP4SCN9ACHRM2 | |
| SCHEMBL19205400 | 0.86 | PTGDR2 (0.48) | PTGDR2PTGDRSCN9AMGLL | |
| SCHEMBL19205343 | 0.78 | PTGDR2 (0.46) | PTGDR2PTGDRSCN9ACHRM2CHRM4 | |
| SCHEMBL19205468 | 0.76 | RBP4 (0.70) | PTGDR2PTGDRRBP4MGLLPTGER2 | |
| SCHEMBL19205379 | 0.74 | PTGDR2 (0.48) | PTGDR2PTGDR | |
| SCHEMBL19205312 | 0.74 | PTGDR2 (0.48) | PTGDR2PTGDRCCNT1CDK9 | |
| SCHEMBL4886140 | 0.72 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2 | |
| Hydrochloric Acid SCHEMBL19205326 | 0.71 | SLC6A2 (0.48) | PTGDR2PTGDRSCN9A | |
| SCHEMBL19291092 | 0.71 | PTGDR2 (0.48) | PTGDR2PTGDRSCN9ACHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3210971-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-16 | — | — | EP | disclosed |
| EP-3210971-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-16 | — | — | EP | disclosed |
| US-9944596-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| US-9944596-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| US-9944596-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| EP-3210971-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-08-30 | — | — | EP | disclosed |
| EP-3210971-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-08-30 | — | — | EP | disclosed |
| US-20170233339-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233339-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RARA | PTGDR2 3817/4885PTGDR 4026/4885RBP4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.